New combo therapy aims to shrink tough head and neck tumors
NCT ID NCT07065630
Summary
This study is testing a new treatment approach for people with a specific type of head and neck cancer that is not linked to HPV. The goal is to see if a combination of a new immunotherapy drug (volrustomig) with two standard chemotherapy drugs can shrink tumors before patients receive their main cancer treatment. Researchers will measure how many patients' tumors shrink significantly and monitor survival and side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The University of Chicago
RECRUITINGChicago, Illinois, 60637, United States
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.